matttyl

Members
  • Content count

    10,329
  • Joined

  • Last visited

Community Reputation

648 Excellent

About matttyl

  • Rank
    Footballguy

Profile Information

  • Gender
    Male

Previous Fields

  • Favorite NFL Team
    Washington Redskins

Recent Profile Visitors

9,718 profile views
  1. Traded him for the #9 rookie pick, and was able to get Dixon with it. Given what's going on in Baltimore, I'm not sure I did the right thing.
  2. Yes, I believe one of his "strikes" was for having a drink with teammates on the team plane.
  3. Stud. Those 3 plays in a row (edited like that I believe) with Kam are great. Guy is legit. Great blitz pickup as well.
  4. At this point we have 11 states with approved rate increases for next year, with an individual market presence of around 3.2 million people. The average, weighted, approved rate increases for next year for those 3.2m in those 11 states - over 30%.
  5. Hadn't even seen a Snorlax in the wild till yesterday, now I've seen two, caught 1. Only like CP63, but at least I got one now.
  6. Illinois average rate increase next year will be 45.1%. Indiana's approved weighted rate increase for next year will be 18.5% (which is one of the better ones thus far).
  7. Check out the "we cut the cable" thread. Tonydead has done a great job in there.
  8. I got the third one, and threw in an extra micro card I had. Using it to run Kodi, and love it.
  9. Sounds like EpiPen has done a great job in getting people to believe they are the only option here.
  10. Serious question - you're the CEO of one of these big insurance companies. Would you rather "keep" 12% of one billion dollars, or 15% of half a billion dollars.
  11. They could. I don't use either, but if I did and the price difference between insurance company A and insurance company B is only $4 a month or so, maybe I'll pay the extra few dollars each month to know the EpiPen is a covered drug. So now insurance company A will get all the folks who use and need EpiPens.
  12. If insurance company A can buy EpiPens for less than company B, then can charge less for their policy and gain more of the market (and likely thus more of the profit). If the pharmaceutical company has a monopoly on the product, though, there is nothing the carrier can do - they have no leverage. It's not rocket science.
  13. Well, it is an interview with a Princeton University health economist with a list of credentials longer than my......well, it's long.
  14. Is Vox a liberal enough source for some of our readers? http://www.vox.com/2016/8/25/12630214/obamacare-marketplaces-death-spiral
  15. Well yes, that's the way it's always been. If you don't pay for insurance, then you don't have insurance. Public subsidies are fine as long as you're getting the money from somewhere.